Mga Batayang Estadistika
| CIK | 1856725 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rani Therapeutics Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 8, 2025 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on August 8, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction o |
|
| August 8, 2025 |
Calculation of Filing Fee Tables S-3 Rani Therapeutics Holdings, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Fo |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| August 7, 2025 |
Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 s |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C |
|
| July 16, 2025 |
424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 4,354,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 3,146,000 Shares of Class A Common Stock We are offering 4,354,000 shares of our Class A common stock, par value $0.0001 per share at the offering price of $0.40 per share of Clas |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com |
|
| July 16, 2025 |
Form of Securities Purchase Agreement, dated July 14, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2025, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| July 16, 2025 |
EX-4.1 Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July , 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| July 11, 2025 |
Up to 13,160,172 Shares of Class A Common Stock Issuable Upon Exercise of Warrant 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-288509 PROSPECTUS Up to 13,160,172 Shares of Class A Common Stock Issuable Upon Exercise of Warrant This prospectus relates to the proposed resale from time to time by the selling stockholder of up to 13,160,172 shares of Class A common stock issuable upon exercise of a Series D common stock warrant. In May 2025, we i |
|
| July 10, 2025 |
DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Rani Therapeutics Holdings, |
|
| July 9, 2025 |
CORRESP July 9, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| July 3, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| June 30, 2025 |
PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Rani Therapeutics Holdings, |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 20, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 20, 2025 |
Exhibit 10.1 RANI THERAPEUTICS HOLDINGS, INC. May 20, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Rani Therapeutics Holdings, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you”, or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s Class A common stock, par |
|
| May 20, 2025 |
Form of Series D Common Stock Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 19, 2025 |
$16,500,000 Class A Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) $16,500,000 Class A Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated August 10, 2022 (the “Base Prospectus”), as supplemented by our prospectus supplement dated August 25, 2022 (the “Prior Prospectus Supplement” and, t |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2025 |
Exhibit 99.1 Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2 |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 16, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidentia |
|
| April 9, 2025 |
Letter of Marcum LLP to the Securities and Exchange Commission dated April 8, 2025 Exhibit 16.1 April 8, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Rani Therapeutics Holdings, Inc. under Item 4.01 of its Form 8-K dated April 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Rani Therapeutics Holdi |
|
| April 9, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| March 31, 2025 |
Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| March 31, 2025 |
Policy Relating to Recovery of Erroneously Awarded Compensation Rani Therapeutics Holdings, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of |
|
| March 31, 2025 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| March 31, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2025 As filed with the U.S. Securities and Exchange Commission on March 31, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organiza |
|
| March 31, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| March 31, 2025 |
INSIDER TRADING POLICY Introduction This policy determines acceptable transactions in the securities of Rani Therapeutics Holdings, Inc. |
|
| November 14, 2024 |
Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agon |
|
| November 14, 2024 |
RANI / Rani Therapeutics Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-rani093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 753018100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| November 14, 2024 |
Exhibit 10.1 AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND SERIES B COMMON STOCK PURCHASE WARRANT This Amendment to Securities Purchase Agreement and Series B Common Stock Purchase Warrant (the “Amendment”) is entered into by and between (the “Holder”) and Rani Therapeutics Holdings, Inc. (the “Company”), effective as of July 23, 2024 (“Amendment Effective Date”). Whereas, Company issued to Holde |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| October 17, 2024 |
Exhibit 99.1 — Joint Filing Agreement, dated October 17, 2024. EX-99.1 2 tm2426414d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join |
|
| October 17, 2024 |
RANI / Rani Therapeutics Holdings, Inc. / South Lake One, Llc - SC 13D/A Activist Investment SC 13D/A 1 tm2426414d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenid |
|
| October 16, 2024 |
Form of Series C Common Warrant Exhibit 4.1 SERIES C COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: October , 2024 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) ( |
|
| October 16, 2024 |
Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: October , 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| October 16, 2024 |
424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 3,000,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 333,333 Shares of Class A Common Stock Series C Common Warrants to Purchase 3,333,333 Shares of Class A Common Stock We are offering 3,000,000 shares of our Class A common stock , |
|
| October 16, 2024 |
Form of Securities Purchase Agreement, dated October 15, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 15, 2024, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| September 11, 2024 |
Letter of Ernst & Young LLP to the Securities and Exchange Commission dated September 11, 2024 Exhibit 16.1 September 11, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated September 11, 2024, of Rani Therapeutics Holdings, Inc. and are in agreement with the statements contained in paragraphs one through four therein under (a) Dismissal of Independent Registered Public Accounting Firm. We have no basis to a |
|
| September 11, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| August 6, 2024 |
Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed equity offering with gross proceeds of approximately $10.0 million - - Presented clinical and precli |
|
| August 6, 2024 |
Collaboration Agreement between Rani Therapeutics, LLC and ProGen Co., Ltd. dated June 17, 2024. Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. Execution Collaboration Agreement By and Between Rani Therapeutics, LLC and ProGen Co., Ltd. Dated June 17, 2024 CONFIDENTI |
|
| August 6, 2024 |
Extension of Intellectual Property Agreement This Extension to Intellectual Property Agreement (the “Extension”) dated June 12, 2024 (the “Effective Date”) is made by and between Mir Imran (“Mir”) and Rani Therapeutics, LLC ("Rani"). |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C |
|
| August 6, 2024 | ||
| July 23, 2024 |
Form of Series B Common Warrant EX-4.2 Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after J |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com |
|
| July 23, 2024 |
424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) 2,800,000 Shares of Class A Common Stock Pre-Funded Warrants to Purchase 446,753 Shares of Class A Common Stock Series A Common Warrants to Purchase 3,246,753 Shares of Class A Common Stock Series B Common Warrants to Purchase 3,246,753 Shares of Class |
|
| July 23, 2024 |
Form of Series A Common Warrant EX-4.1 Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after J |
|
| July 23, 2024 |
Form of Securities Purchase Agreement, dated July 22, 2024. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 22, 2024, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term |
|
| July 23, 2024 |
EX-4.3 Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: Issuance Date: July 23, 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Com |
|
| June 24, 2024 |
Rani Therapeutics and ProGen Collaboration June 24, 2024 Exhibit 99.1 This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act, including statements regarding collaboration between Rani T |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 30, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 6, 2024 |
Exhibit 99.1 Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 – - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half o |
|
| April 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| March 20, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 20, 2024 As filed with the U.S. Securities and Exchange Commission on March 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organiza |
|
| March 20, 2024 |
Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today |
|
| March 20, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America |
|
| March 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| March 20, 2024 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| March 20, 2024 |
Exhibit 10.17 Amendment No. 1 to RMS Service Agreement This Amendment No. 1 to Service Agreement (“the “Amendment”) is made and entered into as of the date of the last signature below (the “Amendment Effective Date”) by and between InCube Labs, LLC, a Delaware limited liability company (“InCube”), and Rani Therapeutics, LLC, a California limited liability company (“Rani”), each a “Party” and colle |
|
| March 20, 2024 |
Exhibit 10.15 Amendment No. 2 to Service Agreement This Amendment No. 2 to Service Agreement (“the “Amendment”) is made and entered into effective as of March 1, 2024 (the “Amendment Effective Date”) by and between InCube Labs, LLC, a Delaware limited liability company (“InCube”), and Rani Therapeutics, LLC, a California limited liability company (“Rani”), each a “Party” and collectively the “Part |
|
| February 5, 2024 |
Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases. |
|
| February 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| February 5, 2024 |
Exhibit 99.1 Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints – |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| December 8, 2023 |
RANI / Rani Therapeutics Holdings Inc Class A / South Lake One, Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las |
|
| December 8, 2023 |
Exhibit 99.1 — Joint Filing Agreement, dated December 8, 2023. EX-99.1 2 tm2332511d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Isidoro Alfonso Quiroga Cortés Aequanimitas Limited Partnership Avenida Presidente Riesco 5711 |
|
| December 8, 2023 |
Exhibit 99.1 — Joint Filing Agreement, dated December 8, 2023. EX-99.1 2 tm2332511d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| November 8, 2023 |
Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET SHORELINE BUSINESS CENTER FREMONT, CA LANDLORD: BKM SOUTH BAY 240, |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| November 8, 2023 |
Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 |
|
| November 1, 2023 |
Exhibit 99.1 Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results - Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| October 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) ( |
|
| October 25, 2023 |
Exhibit 99.1 The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Daily administration for 60 days was well-tolerated with no treatment-related adverse events - - Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies - SAN JOSE, Calif., October 25, 2023 - Rani Th |
|
| September 7, 2023 |
Exhibit 99.1 Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies - Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased pay |
|
| September 7, 2023 |
Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases. |
|
| September 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| August 11, 2023 |
Exhibit 10.1 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. License and Supply Agreement By and Between Rani Therapeutics, LLC and Celltrion, Inc. Dated May 26, 2023 CONFIDENTIAL Lice |
|
| August 11, 2023 |
Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2023 |
Exhibit 10.2 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. Rani Therapeutics, LLC. Date Kate McKinley [*] Re: Offer of Employment Dear Kate, Rani Therapeutics, LLC. (the “Company”) i |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 30, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 10, 2023 |
Exhibit 99.1 Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Initiation of Phase 2 c |
|
| April 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| March 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| March 22, 2023 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| March 22, 2023 |
Exhibit 10.21 August 31, 2022 Svai Sanford VIA EMAIL Re: Amended and Restated Employment Agreement Dear Svai: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of September |
|
| March 22, 2023 |
Exhibit 10.19 August 31, 2022 Talat Imran VIA EMAIL Re: Amended and Restated Employment Agreement Dear Talat: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of September |
|
| March 22, 2023 |
Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for R |
|
| March 22, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 List of subsidiaries of Rani Therapeutics Holdings, Inc. Name of Subsidiary Jurisdiction of Organization Rani Therapeutics, LLC California, United States of America |
|
| March 22, 2023 |
Exhibit 10.27 Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential. Omitted portions are indicated by [*]. License and Supply Agreement By and Between Rani Therapeutics, LLC and Celltrion, Inc. Dated January 6, 2023 CONFIDENTIAL |
|
| March 22, 2023 |
Exhibit 10.20 August 31, 2022 Mir Hashim VIA EMAIL Re: Amended and Restated Employment Agreement Dear Mir Hashim: You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of Septe |
|
| March 22, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 22, 2023 S-8 1 2023forms-8.htm S-8 As filed with the U.S. Securities and Exchange Commission on March 22, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of |
|
| March 15, 2023 |
RANI / Rani Therapeutics Holdings Inc Class A / South Lake One, Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las |
|
| March 15, 2023 |
Exhibit 99.1 — Joint Filing Agreement, dated March 15, 2023. EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of March 15, 2023. Sout |
|
| January 9, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) ( |
|
| January 5, 2023 |
Exhibit 99.1 Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., January 5, 2023 - Rani Therapeutics Hold |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) ( |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) |
|
| December 29, 2022 |
6,009,542 Shares of Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-268855 6,009,542 Shares of Class A Common Stock This prospectus relates to the resale from time to time of up to 6,009,542 shares of our Class A common stock, or the shares, including 533,740 shares issuable upon exchange of Class A common units of Rani Therapeutics, LLC, or LLC Interests, which are held by the selling stockho |
|
| December 27, 2022 |
RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 December 27, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-268855 Acceleration Request Requested Date: December 29, |
|
| December 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| December 16, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 16, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on December 16, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of inco |
|
| December 6, 2022 |
Exhibit 99.1 Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill? GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) |
|
| December 6, 2022 |
RT-102 Phase I Study Part 2: Repeat-Dose Update December 2022 RT-102 Phase I Study Part 2: Repeat-Dose Update December 2022 This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| November 10, 2022 |
Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn?s disease and psoriasis - - Announced RT-102 P |
|
| October 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) ( |
|
| October 24, 2022 |
Exhibit 99.1 Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update - Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn?s disease and psoriasis - - RT-102 Phase 1 repeat-dose topline data anticipated in 4Q 2022 - - Initiation of in |
|
| August 25, 2022 |
EX-1.1 2 d385381dex11.htm EX-1.1 Exhibit 1.1 Rani Therapeutics Holdings, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 24, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Rani Therapeutics Holdings, Inc., a Delaware c |
|
| August 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C |
|
| August 25, 2022 |
Up to $150,000,000 Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 10, 2022) Up to $150,000,000 Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, dated August 25, 2022, or the Sales Agreement, with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, collectively, the Agents, relating to the sa |
|
| August 11, 2022 |
SUBJECT TO COMPLETION, AUGUST 10, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266444 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities offered hereby has been declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus supplement and t |
|
| August 10, 2022 |
Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of August 8, 2022 between Rani Therapeutics, LLC (?Borrower?) and Rani Management Services, Inc. , as a guarantor and Rani Therapeutics Holdings, Inc., as a guarantor (together with Rani Management Services, Inc., each, individually, a ?Guarantor,? and collectively, ?Guarantors?)) and Avenue Venture Opportunities Fund, L.P., a Del |
|
| August 10, 2022 |
Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 The following is a description of the Class A common stock, par value $0.0001 per share (the ?Class A common stock?) of Rani Therapeutics Holdings, Inc. (?Rani?, the ?Company?, ?we?, ?our? or ?us?) which is our only class of security registered under Section 12 of the Sec |
|
| August 10, 2022 |
RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-266444 Ladies and Gentlemen: The under |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| August 10, 2022 |
RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-266444 Acceleration Request Requested Date: August 10, 2022 Req |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40672 86-3114789 (State or Other Jurisdiction of Incorporation) (C |
|
| August 10, 2022 |
Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES REPRESENTED BY THIS WARRANT HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERW |
|
| August 10, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of August 8, 2022 among RANI THERAPEUTICS, LLC, a California limited liability company, as ?Borrower?, RANI MANAGEMENT SERVICES, INC., a Delaware corporation, and as a guarantor RANI THERAPEUTICS HOLDINGS, INC., a Delaware corporation, as a guarantor (together with Rani Management Services, each, individually, a ?Guarantor,? and collectively, the ? |
|
| August 10, 2022 |
Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., August 10, 2022 - Rani Therapeutics Holdings, Inc. (?Rani Therap |
|
| August 9, 2022 |
RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 August 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Alan Campbell Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-266444 Acceleration Request Requested Date: August 11, 2022 Requ |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| August 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 1, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on August 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorpo |
|
| August 1, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.8 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national bank |
|
| August 1, 2022 |
Form of Class A Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT THIS CLASS A COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] |
|
| August 1, 2022 |
Exhibit 4.4 RANI THERAPEUTICS HOLDINGS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1?DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2?ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| August 1, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 RANI THERAPEUTICS HOLDINGS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF , 20 RANI THERAPEUTICS HOLDINGS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national bank |
|
| August 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 11, 2022 |
EX-99.1 Exhibit 99.1 Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE, Calif., May 11, 2022 — Rani Therapeutics Hold |
|
| May 11, 2022 |
Exhibit 10.2 RANI THERAPEUTICS, LLC April 12, 2022 Eric Groen VIA EMAIL Re: Employment Agreement Dear Eric: You are currently employed by RANI MANAGEMENT SERVICES, INC. (?RMS?) under the terms of an offer letter between you and RMS dated July 29, 2021 (the ?Offer Letter?). Your employment is being transitioned to Rani Therapeutics, LLC (the ?Company?) and this employment agreement (the ?Agreement? |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Comm |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| April 13, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? ? ? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission O |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 31, 2022 |
Exhibit 10.1 TAX RECEIVABLE AGREEMENT between RANI THERAPEUTICS HOLDINGS, INC. and THE PERSONS NAMED HEREIN Dated as of August 3, 2021 Table of Contents Article I DEFINITIONS Section 1.1 Definitions Article II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT Section 2.1 Basis Schedule Section 2.2 Tax Benefit Schedule Section 2.3 Procedures, Amendments Section 2.4 Basis Adjustments Article III TAX BEN |
|
| March 31, 2022 |
Forms of Agreement under the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan. Exhibit 10.8 [FORM OF STANDARD OPTION GRANT PACKAGE] RANI THERAPEUTICS HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Rani Therapeutics Holdings, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (as may be amended and/or restated as of the Date of Grant set forth below, the ?Plan?), has granted to Optionholder an option to purchase the number of shares of the C |
|
| March 31, 2022 |
Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 The following is a description of the Class A common stock, par value $0.0001 per share (the ?Class A common stock?) of Rani Therapeutics Holdings, Inc. (?Rani?, the ?Company?, ?we?, ?our? or ?us?) which is our only class of security registered under Section 12 of the Sec |
|
| March 31, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Rani Therapeutics Holdings, Inc. |
|
| March 31, 2022 |
Registration Rights Agreement, effective as of August 3, 2021 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT BY AND AMONG RANI THERAPEUTICS HOLDINGS, INC. AND THE ?INVESTORS? as defined herein, Dated as of August 3, 2021 Table of Contents Page 1. DEFINITIONS 1 2. REGISTRATION RIGHTS 3 2.1 Demand Registration. 3 2.2 Shelf Take-Downs 4 2.3 Company Registration 5 2.4 Underwriting Requirements. 5 2.5 Obligations of the Company 6 2.6 Furnish Information 8 2.7 Expense |
|
| March 31, 2022 |
Exhibit 10.14 Amendment No. 1 to Service Agreement This Amendment No. 1 to Service Agreement (?the ?Amendment?) is made and entered into effective as of March 21, 2022 (the ?Amendment Effective Date?) by and between InCube Labs, LLC, a Delaware limited liability company (?InCube?), and Rani Therapeutics, LLC, a California limited liability company (?Rani?), each a ?Party? and collectively the ?Par |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| March 31, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2022 As filed with the U.S. Securities and Exchange Commission on March 31, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of Incorporation or organiza |
|
| March 31, 2022 |
Exhibit 10.4 RANI THERAPEUTICS, LLC FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of August 3, 2021 THE UNITS REPRESENTED BY THIS FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR |
|
| March 31, 2022 |
Exhibit 10.2 EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?) is made and entered into as of August 3, 2021, by and between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?) and the persons and entities (each, a ?Contributor? and collectively, the ?Contributors?) listed on Schedule I below. Each of the Contributors and the Company shall be known as a ?Party? her |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| March 29, 2022 |
Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update - Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill? HC, capable of delivering payloads of up to 20 mg - - Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty ? - Conference call |
|
| March 23, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (Co |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| February 23, 2022 |
Rani Therapeutics Announcing RaniPill? HC February 2022 Exhibit 99.2 Forward Looking Statements This presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith beliefs and assumptions as of that time with respect to future events, and are subj |
|
| February 23, 2022 |
Exhibit 99.1 Rani Therapeutics Unveils High-Capacity RaniPill? Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results - Preclinical data demonstrates new RaniPill? HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill? capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 753018100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 1, 2022 |
Power of Attorney granted by Isidoro Quiroga Moreno, dated October 20, 2021. EX-99.1 2 tm225035d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 GENERAL POWER OF ATTORNEY ISIDORO ERNESTO QUIROGA MORENO, Chilean, married, businessman, national identity card number 6.397.675-K, domiciled on the First and Second Floor 28-29 Hans Place, London, SW1X OJY, hereinafter the “Principal,” hereby grants a full power of attorney, as broad as corresponds by law, to: a/ Luis Felipe Correa González |
|
| February 1, 2022 |
EXHIBIT 99.2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of February 1, 2022. Is |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Isidoro Alfonso Quiroga Cortés Aequanimitas Limited Partnership Avenida Presidente Riesco 5711 Ofi |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa González South Lake One LLC Avenida Presidente Riesco 5711 Oficina 1603, Las |
|
| February 1, 2022 |
SCHEDULE 13D JOINT FILING AGREEMENT EXHIBIT 99.1 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing Agreement as of February 1, 2022. Ae |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2022 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) (C |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number: 001-40672 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR ? For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| November 16, 2021 |
Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update Exhibit 99.1 Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update SAN JOSE, Calif., November 15, 2021?Rani Therapeutics Holdings, Inc. (?Rani Therapeutics? or ?Rani?) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corpor |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| November 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| September 29, 2021 |
Redefining Oral Biologics September 2021 Exhibit 99.1 This presentation and the accompanying oral statements contain forward-looking statements. Forward-looking statements are based on information available at the time those statements are made or on management's good faith beliefs and assumptions as of that time with respect to future events, and are subject to risks and uncertainties that could |
|
| September 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| September 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40672 86-3114789 (State or other jurisdiction of incorporation) |
|
| September 13, 2021 |
EX-99.1 2 d203844dex991.htm EX-99.1 Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update - IPO in July 2021 raised $84.3 million in gross proceeds - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors’ appointments - SAN JOSE, Calif., September 13, 2021—Rani Therapeutics Holdings, I |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40672 RANI THERAPEUTICS HOLDINGS, INC. |
|
| August 23, 2021 |
RANI / Rani Therapeutics Holdings, Inc. Class A / InCube Labs, L.L.C. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Mir Imran InCube Labs, L.L.C. c/o Rani Therapeutics Holdings, Inc. 2051 Ringwood Avenue San Jose, California 951 |
|
| August 23, 2021 |
SCHEDULE 13D JOINT FILING AGREEMENT EX-99.5 2 d217819dex995.htm EX-99.5 Exhibit 99.5 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Joint Filing |
|
| August 9, 2021 |
RANI THERAPEUTICS HOLDINGS, INC. EXHIBIT 99.2 RANI THERAPEUTICS HOLDINGS, INC. BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated Cantor Fitzgerald & Co. Canaccord Genuity LLC as Representative(s) of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th |
|
| August 9, 2021 |
Exhibit 99.3 — Schedule 13D Joint Filing Agreement. EX-99.3 4 tm2124473d1ex99-3.htm EXHIBIT 99.3 EXHIBIT 99.3 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this Joint Filing Agreement is attached and have duly executed this Join |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Rani Therapeutics Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 753018 100 (CUSIP Number) Luis Felipe Correa Gonz?lez South Cone Investments Limited Partnership Avenida Presidente Riesco 5 |
|
| August 9, 2021 |
— Lock-Up Letter addressed to the Underwriters executed by South Lake One, dated April 16, 2021. EX-99.1 2 tm2124473d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 RANI THERAPEUTICS HOLDINGS, INC. BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated Cantor Fitzgerald & Co. Canaccord Genuity LLC as Representative(s) of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Stifel, Nicolaus & C |
|
| August 3, 2021 |
As filed with the U.S. Securities and Exchange Commission on August 3, 2021 As filed with the U.S. Securities and Exchange Commission on August 3, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rani Therapeutics Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of Incorporation or organiza |
|
| August 2, 2021 |
6,666,667 Shares Class A Common Stock 424B4 1 d151628d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257809 6,666,667 Shares Class A Common Stock This is the initial public offering of shares of Class A common stock of Rani Therapeutics Holdings, Inc., par value $0.0001. We are offering 6,666,667 shares of our Class A common stock. Prior to this offering, there has been no public market for our |
|
| July 30, 2021 |
FWP 1 d207278dfwp.htm FWP Issuer Free Writing Prospectus dated July 30, 2021 Filed Pursuant to Rule 433 of the Securities Act of 1933 Relating to Preliminary Prospectus dated July 26, 2021 Registration Statement No. 333-257809 This free writing prospectus relates only to the securities described below and should be read together with the preliminary prospectus dated July 26, 2021 relating to this |
|
| July 27, 2021 |
July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tracey McKoy Kevin Kuhar Kasey Robinson Laura Crotty Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-1 Submitted July 9, 2021, as amended File No. 333-257809 Acceleration Request Requested Date: July 29, 2021 Requested Time: 4:00 p.m. |
|
| July 27, 2021 |
RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 RANI THERAPEUTICS HOLDINGS, INC. 2051 Ringwood Avenue San Jose, California 95131 July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tracey McKoy Kevin Kuhar Kasey Robinson Laura Crotty Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-1, as amended (File No. 333-257809) Request for Acce |
|
| July 26, 2021 |
Exhibit 10.26 RANI MANAGEMENT SERVICES, INC. June 17, 2021 Mir Hashim VIA EMAIL Re: Amended and Restated Employment Agreement Dear Mir: You are currently employed by RANI MANAGEMENT SERVICES, INC. (the ?Company?) under the terms of an offer letter between you and the Company dated December 3, 2019 (the ?Offer Letter?). The Company is amending and restating the terms of the Offer Letter to reflect |
|
| July 26, 2021 |
Exhibit 4.1 RT CUSIP 753018 10 0 INCORPORATED UNDER THE LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: AMERICAN COUNTERSIGNED is the record holder of STOCK AND FULLY PAID AND NONASSESSABLE SHARES OF CLASS A COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF (BROOKLYN, RANI THERAPEUTICS HOLDINGS, INC. TRANSFER transferable on the books of the Corpor |
|
| July 26, 2021 |
8-A12B 1 d193678d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Rani Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3114789 (State or other jurisdiction of incorporation or organi |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 26, 2021 Registration No. |
|
| July 26, 2021 |
Exhibit 1.1 Rani Therapeutics Holdings, Inc. (a Delaware corporation) [●] Shares of Class A Common Stock UNDERWRITING AGREEMENT Dated: [●], 2021 Rani Therapeutics Holdings, Inc. (a Delaware corporation) [●] Shares of Class A Common Stock UNDERWRITING AGREEMENT [●], 2021 BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated Cantor Fitzgerald & Co. Canaccord Genuity LLC as Representative(s |
|
| July 26, 2021 |
Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan. EX-10.8 7 d151628dex108.htm EX-10.8 Exhibit 10.8 RANI THERAPEUTICS HOLDINGS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN Adopted by the Board of Directors: July 23, 2021 Approved by the Stockholders: July 23, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. |
|
| July 26, 2021 |
Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan. EX-10.7 6 d151628dex107.htm EX-10.7 Exhibit 10.7 RANI THERAPEUTICS HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 23, 2021 Approved by the Stockholders: July 23, 2021 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maxi |
|
| July 26, 2021 |
EX-3.1 3 d151628dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RANI THERAPEUTICS HOLDINGS, INC. Rani Therapeutics Holdings, Inc., a Delaware corporation, hereby certifies that: ONE: The name of this corporation is Rani Therapeutics Holdings, Inc. This corporation filed its original Certificate of Incorporation with the Secretary of State of the State of Delaware |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 16, 2021 Amendment No. 1 to Form S-1 As filed with the Securities and Exchange Commission on July 16, 2021 Registration No. 333-257809 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 RANI THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3114789 (Stat |
|
| July 16, 2021 |
Exhibit 10.4 RANI THERAPEUTICS, LLC FORM OF FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of [ ], 2021 THE UNITS REPRESENTED BY THIS FIFTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED |
|
| July 16, 2021 |
Exhibit 10.11 RANI THERAPEUTICS HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Rani Therapeutics Holdings, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensatio |
|
| July 16, 2021 |
Form of Tax Receivable Agreement, to be effective upon the closing of this offering. Exhibit 10.1 FORM OF TAX RECEIVABLE AGREEMENT between RANI THERAPEUTICS HOLDINGS, INC. and THE PERSONS NAMED HEREIN Dated as of [ ] TABLE OF CONTENTS ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT 11 Section 2.1 Basis Schedule 11 Section 2.2 Tax Benefit Schedule 11 Section 2.3 Procedures, Amendments 12 Section 2.4 Basis Adjustments 12 ART |
|
| July 16, 2021 |
Exhibit 10.2 FORM OF EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into as of [?], 2021, by and between Rani Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?) and the persons and entities (each, a ?Contributor? and collectively, the ?Contributors?) listed on Schedule I below. Each of the Contributors and the Company shall be known as a ?Party? |
|
| July 16, 2021 |
Form of Registration Rights Agreement, to be effective upon the closing of this offering. EX-10.3 4 d151628dex103.htm EX-10.3 Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT BY AND AMONG RANI THERAPEUTICS HOLDINGS, INC. AND THE “INVESTORS” as defined herein, Dated as of [●], 2021 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. REGISTRATION RIGHTS 4 2.1 Demand Registration 4 2.2 Shelf Take-Downs 6 2.3 Company Registration 6 2.4 Underwriting Requirements 7 2.5 Obligations of the Company 8 |
|
| July 9, 2021 |
Exhibit 10.15 InCube Labs, LLC – Rani Therapeutics, LLC SERVICE AGREEMENT This service agreement (this “Agreement”), is made and entered into effective as of January 1, 2021 (the “Effective Date”) by and between InCube Labs, LLC, a Delaware limited liability company (“InCube”), and Rani Therapeutics, LLC, a California limited liability company (“Rani”), each a “Party” and collectively the “Parties |
|
| July 9, 2021 |
Exhibit 10.23 RANI MANAGEMENT SERVICES, INC. June 17, 2021 Talat Imran VIA EMAIL Re: Amended and Restated Employment Agreement Dear Talat: You are currently employed by RANI MANAGEMENT SERVICES, INC. (the “Company”) under the terms of an offer letter between you and the Company dated December 28, 2020 (the “Offer Letter”). The Company is amending and restating the terms of the Offer Letter to refl |
|
| July 9, 2021 |
Exhibit 10.12 RANI THERAPEUTICS, LLC InCube Labs, LLC 2051 Ringwood Ave San Jose, CA 95131 Attention: Mir Imran RE: Acknowledgement and Amendment to the: (i) Intellectual Property Agreement, dated June 14, 2012 (“IPA”), (ii) Service Agreement, dated January 1, 2013 (“Services Agreement”), and (iii) Exclusive License Agreement, dated June 14, 2012 (“License Agreement”) – each as between Rani Therap |
|
| July 9, 2021 |
Power of Attorney (reference is made to the signature page thereto). Table of Contents As filed with the Securities and Exchange Commission on July 9, 2021 Registration No. |
|
| July 9, 2021 |
EX-10.8 10 d151628dex108.htm EX-10.8 Exhibit 10.8 RANI THERAPEUTICS HOLDINGS, INC. SEVERANCE AND CHANGE IN CONTROL PLAN Section 1. INTRODUCTION. The Rani Therapeutics Holdings, Inc. Severance and Change in Control Plan (the “Plan”) is hereby established by the Board of Directors of Rani Therapeutics Holdings, Inc. (the “Company”) effective upon the IPO Date (as defined below). The purpose of the P |
|
| July 9, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF RANI THERAPEUTICS HOLDINGS, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 5 Section 7. Notic |
|
| July 9, 2021 |
Exhibit 10.4 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [ ], is made by and between RANI THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Company” or “Rani” ), and (“Indemnitee” ). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s amended and res |
|
| July 9, 2021 |
Exhibit 10.17 Amended and Restated Exclusive License Agreement This exclusive license agreement (this ?Agreement?) is made by and between InCube Labs, LLC (?InCube? or ?Licensor?) a Delaware limited liability company having an address at 2051 Ringwood Ave., San Jose, CA 95131, and Rani Therapeutics, LLC (?Rani? or ?Licensee?), a California limited liability company having an address at 2051 Ringwo |
|
| July 9, 2021 |
CORRESP 1 filename1.htm Josh Seidenfeld +1 650 843 5862 [email protected] July 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Kevin Kuhar Tracey McKoy Lauren Hamill Laura Crotty Re: Rani Therapeutics Holdings, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted June 22, 2021 CIK No. 0001856 |
|
| July 9, 2021 |
Exhibit 10.20 LOAN AND SECURITY AGREEMENT Dated as of September 15, 2020 between RANI THERAPEUTICS, LLC, a California limited liability company, as “Borrower”, and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership, as “Lender” LOAN AND SECURITY AGREEMENT Borrower and Lender have entered or anticipate entering into one or more transactions pursuant to which Lender agrees to ma |
|
| July 9, 2021 |
Exhibit 10.22 SUPPLEMENT to the Loan and Security Agreement dated as of September 15, 2020 between Rani Therapeutics, LLC (“Borrower”) and Avenue Venture Opportunities Fund, L.P. (“Lender”) This is a Supplement identified in the document entitled Loan and Security Agreement, dated as of September 15, 2020 (as amended, restated, supplemented and modified from time to time, the “Loan and Security Ag |
|
| July 9, 2021 |
Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.6 RANI THERAPEUTICS HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [ ], 2021 APPROVED BY THE STOCKHOLDERS: [ ], 2021 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company a |
|
| July 9, 2021 |
Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan. Exhibit 10.7 RANI THERAPEUTICS HOLDINGS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [ ], 2021 APPROVED BY THE STOCKHOLDERS: [ ], 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a seri |
|
| July 9, 2021 |
EX-10.11 13 d151628dex1011.htm EX-10.11 Exhibit 10.11 RANI-InCube Labs IP Agreement RANI-InCube Labs Intellectual Property Agreement This agreement dated June 14, 2012, is hereby made by and between InCube Labs LLC (“InCube”) and Rani Therapeutics, LLC. (“RANI”), both having an address at 2051 Ringwood Ave, San Jose CA 95131 1. Definitions As used herein, (i) “Field” means “ORAL DELIVERY OF BIOTHE |
|
| July 9, 2021 |
Exhibit 10.24 RANI MANAGEMENT SERVICES, INC. June 17, 2021 Mir Hashim VIA EMAIL Re: Amended and Restated Employment Agreement Dear Mir: You are currently employed by RANI MANAGEMENT SERVICES, INC. (the ?Company?) under the terms of an offer letter between you and the Company dated December 3, 2019 (the ?Offer Letter?). The Company is amending and restating the terms of the Offer Letter to reflect |
|
| July 9, 2021 |
Exhibit 10.19 Intellectual Property Agreement This agreement (the ?Agreement?) dated June 22, 2021 (the ?Effective Date?) is hereby made by and between Mir A. Imran (?Mir?), an individual residing at 12894 Brendel Dr., Los Altos, CA 94022, in his personal capacity, and Rani Therapeutics, LLC (?Rani?), a California company having an address at 2051 Ringwood Ave., San Jose, CA 95131. Mir and Rani ma |
|
| July 9, 2021 |
EX-10.18 20 d151628dex1018.htm EX-10.18 Exhibit 10.18 Non-Exclusive License Agreement This non-exclusive license agreement (this “Agreement”) is made by and between Rani Therapeutics, LLC (“Rani” or “Licensor”), a California limited liability company having an address at 2051 Ringwood Ave., San Jose, CA 95131, and InCube Labs, LLC (“InCube” or “Licensee”), a Delaware limited liability company havi |
|
| July 9, 2021 |
Exhibit 10.13 InCube Labs, LLC SERVICE AGREEMENT This SERVICE AGREEMENT (“Agreement”), is made and entered into effective as of January 1, 2019 (the “Effective Date”) by and between Rani Therapeutics, LLC (“Rani”) and InCube Labs, LLC (“InCube”) (collectively referred to as the “Parties”), in reference to the following: WHEREAS, InCube is in the business of inventing, creating, incubating, develop |
|
| July 9, 2021 |
Exhibit 10.10 EXCLUSIVE LICENSE AGREEMENT between InCube Labs, LLC. (?Licensor?) and Rani Therapeutics, LLC (?Licensee?) EXCLUSIVE LICENSE AGREEMENT This exclusive license agreement (the ?Agreement?) is made effective on June 14, 2012 (the ?Effective Date?), between InCube Labs, LLC (?Licensor?), and Rani Therapeutics, LLC, a California limited liability corporation (?Licensee?). BACKGROUND A. Cer |
|
| July 9, 2021 |
Exhibit 10.21 PROMISSORY NOTE Note No. 1 $3,000,000.00 September 15, 2020 The undersigned (“Borrower”) promises to pay to the order of AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Lender”), at such place as Lender may designate in writing, in lawful money of the United States of America, the principal sum of Three Million Dollars ($3,000,000.00), with interest thereon |
